EASD 2020 Highlights

Conference summaries


CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries

Presented by:

Ofri Mosenzon, MD, PhD

  • CAPTURE estimated the prevalence of CVD in almost 10,000 adults with T2D from 13 countries.
  • In 2019, around one-third of adults with T2D had established CVD.
  • Less than one-fourth of adults with T2D and established CVD were being prescribed a glucose-lowering agent with demonstrated CV benefit.

What do we already know about this topic?

  • Cardiovascular disease (CVD) comprises the largest cause of morbidity and mortality in people with type 2 diabetes (T2D).1
  • There is a paucity of data on the prevalence of CVD among people with T2D.
  • Recent findings from cardiovascular (CV) outcomes trials showed a CV benefit with some GLP-1 receptor agonists and SGLT-2 inhibitors and are changing treatment recommendations.2
  • Understanding the impact of this paradigm shift requires data on the prevalence of CVD in people with T2D.

How was this study conducted?

  • CAPTURE was a multinational, cross-sectional, non-interventional study of adults aged ≥18 years with T2D attending a single routine healthcare visit in primary or specialist care between December 2018 and September 2019.
  • The primary endpoint was overall prevalence estimate of CVD across all 13 countries, weighted to account for the size of the diabetes population of each country.

What does this study add?

  • 9823 participants were included, 4502 from primary care and 5321 from specialist care.
  • Overall weighted CVD prevalence was estimated at 34.8% (95% CI 32.7-36.8%), which was similar across primary (35.6%) and specialist care (32.1%).
  • Overall weighted atherosclerotic cardiovascular disease (ASCVD) prevalence was estimated at 31.8% (95% CI 29.7-33.8), which was similar across primary (30.3%) and specialist care (32.1%).
  • Those with CVD were older than those without (68 vs. 62 years), with longer duration of diabetes (13.0 vs. 9.8 years).
  • Use of CV medications was greater in patients with CVD, with no differences in use of glucose-lowering medications in those with and without CVD.
  • Less than 25% of patients overall used a glucose-lowering agent with demonstrated CV benefit, with similar rates in those with and without CVD.


How does this study impact clinical practice?

  • CAPTURE is a cross-sectional study that estimated the prevalence of CVD in nearly 10,000 adults with T2D from 13 countries using standardised methodology.
  • In 2019, approximately one in three adults with T2D attending a primary or specialist healthcare visit had established CVD.
  • Fewer than one and four adults with T2D and established CVD used a glucose-lowering agent with demonstrated CV benefit.
  • Future studies are required to evaluate the implementation and impact of the recent updates to T2D and cardiology treatment guidelines.



  1. Gerstein HC. Diabetes: Dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11(9):508-10.
  2. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221-8.


Related content

  • Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83.


This is a highlights summary of an oral session given at the EASD 2020 Virtual Meeting and presented by:

Ofri Mosenzon, MD, PhD
Ichan School of Medicine at Mount Sinai, New York, NY, USA

The presenting authors of the original session had no part in the creation of this conference highlights summary. 

The content is produced by Infomedica. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Florian Toti, MD, the scientific editor of the program.


20 years HAPO Study: What have we learned so far?

Presented by: Patrick M. Catalano, MD
Expert commentary by Elizabeth O. Buschur, MD


Empagliflozin for the treatment of chronic heart failure and a reduced ejection fraction in patients with and without diabetes: new results of the EMPEROR-Reduced trial

Presented by: Javed Butler, MD; Milton Packer, MD; Stefen D.Anker, MD; Gerasimos Filippatos, MD; Faiez Zannad, MD
Expert commentary by Prof. Francesco Giorgino


After completing the program, test your knowledge with this quiz.

Keep learning Go